Akero Therapeutics Inc buy Canaccord Genuity Group Inc.
Start price
21.03.23
/
50%
€34.60
Target price
21.03.24
€53.84
Performance (%)
-31.21%
End price
22.03.24
€23.80
Summary
This prediction ended on 22.03.24 with a price of €23.80. The BUY prediction by Canaccord_Genuity_Gr for Akero Therapeutics Inc performed very badly with a performance of -31.21%. Canaccord_Genuity_Gr has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Akero Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | -2,80 % | -1,40 % | -0,22 % | 48,43 % |
| iShares Nasdaq 100 | -6,35 % | -0,41 % | 29,00 % | 84,28 % |
| iShares Nikkei 225® | -6,94 % | -0,28 % | 48,21 % | 59,28 % |
| iShares S&P 500 | -3,41 % | 0,40 % | 20,28 % | 62,51 % |
Comments by Canaccord_Genuity_Gr for this prediction
In the thread Akero Therapeutics Inc diskutieren
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $58.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
In the thread Trading Akero Therapeutics Inc
Die von Canaccord_Genuity_Gr gewählte maximale Laufzeit wurde überschritten